After an acute coronary syndrome event, alirocumab may offer greater risk reductions for future cardiovascular events in patients with diabetes vs those without diabetes, according to study results published in The Lancet Diabetes & Endocrinology. In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; ClinicalTrials.gov Identifier:…
ARO-ANG3 reduces production of ANGPTL3, which has been shown to lower serum LDL as well as serum and liver triglyceride.
Ezallor Sprinkle is intended for patients who have difficulty swallowing.
With a growing number of patients with both diabetes and cardiovascular disease, clinicians consider the need for a new specialty: cardiometabolic medicine.
Elevated lipoprotein(a) and corresponding LPA genotypes are also associated with an increased risk for ischemic stroke, although the incremental risk is less pronounced.
People living with HIV, non-alcoholic fatty liver disease, and antiretroviral-associated lipodystrophy may be at an increased risk of developing type 2 diabetes.
Adding proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) to background niacin therapy is shown to reduce lipoprotein(a) (Lp[a]) by approximately 15%, according to study results published in the Journal of Clinical Lipidology. In this study, 150 patients were divided into 2 groups: 136 received PCSK9i monotherapy and 14 received PCSK9i and niacin combination therapy. PCSK9i…
Measurement of serum apolipoprotein levels in apolipoprotein-defined lipoprotein subclasses may have an important role in predicting vascular complications in T1D.
Glucose-lowering medications and high-intensity statins are not being used sufficiently among high-risk individuals with atherosclerotic cardiovascular disease and diabetes.
There may be a dose-dependent relationship between statin therapy and new-onset diabetes across the duration of statin use.
